ArticleOral diseases2025
Differences in Oral Squamous Cell Carcinoma From Colombia and Spain: A Retrospective Cohort Study.
Article in Oral diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Changes in gingival cancer: burden of hospitalization and epidemiological evolution from 2001 to 2023 in Spain. a novel approach using hospital activity registry data.BMC oral health · 2026Article
- Evaluation of survival rate in patients with tongue squamous cell carcinoma: a retrospective single-center study.BMC oral health · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
objectiveTo compare the clinicopathological characteristics and survival of two cohorts of patients with oral squamous cell carcinoma (OSCC) from Spain and Colombia.
methodsClinicopathological and survival variables of patients with OSCC from six maxillofacial surgery departments in Spain and Colombia were retrospectively reviewed. Variables were compared according to country of origin.
resultsWe included 649 patients, 359 from Spain and 290 from Colombia. The Colombian cohort was younger, drank more alcohol, had less comorbidities, and reported a greater mean number of days both from symptoms to diagnosis and from then to treatment, which was ∼2.5 times longer in the Colombian cohort. Colombian patients were diagnosed at a more advanced stage. The treatment of choice was resective surgery. In the Colombian cohort, more patients received radio and chemotherapy together with surgery. Second primary tumors and recurrences were more frequent in the Colombian sample (7.2% vs. 2.8%; p = 0.008) and in the Spanish cohort (32% vs. 23.1%; p = 0.012), respectively. Overall survival was similar between the two samples (HR = 1.15; 95% CI = 0.93-1.42; p = 0.195) and disease-specific survival was worse in the Colombian one (HR = 1.30; 95% CI = 1.03-1.65; p = 0.027).
conclusionsThere were epidemiological differences between patients with OSCC in both cohorts and a longer delay in diagnosis and treatment in the Colombian sample.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.